Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Canadian co-founder of Moderna wins science award for mRNA research

06/23/2021 | 05:22pm EDT

The Canadian co-founder of Moderna says he's proud to have won a prestigious European science award that counts esteemed scientists such as Stephen Hawking among its previous recipients.

Derrick Rossi, who was born in Toronto and now lives in the Boston area, won the 2021 Princess of Asturia award for his work on the mRNA technology that led to the creation of COVID-19 vaccines.

"It's a great honour and what makes it a really great honour for me is that I've looked at past recipients of this award and it's a very, very distinguished company to be amongst," said Rossi.

"It's humbling and exciting."

He won alongside multiple other researchers based in Hungary, Germany, the U.K. and the U.S who's work also contributed to designing the vaccine.

The panel for the award calls them leading figures in one of the most outstanding feats in the history of science for leading the way to developing vaccines in an extraordinarily short space of time.

The COVID-19 vaccines by Pfizer and Moderna both use mRNA technology, and it's the first time the technology has been used for a vaccine.

Rossi, who is no longer with Moderna and is working on multiple other initiatives, says it was always his goal to have his work affect human health in a positive way.

"Of course you want to see your work make an impact," said Rossi.

"It's satisfying, but did I imagine that it would happen in a global pandemic and Moderna would become a household name ... No I didn't imagine that, but I always believed mRNA was going to make an impact."

He said he's continuing to try and improve people's lives through science, and has now turned much of his attention to combatting the effects of venomous snake bites in poorer countries.

Rossi said snake bites kill more than 100,000 people per year and maim hundreds of thousands of more, and called the issue a massive global health crisis.

This report by The Canadian Press was first published June 23, 2021.

— With files from The Associated Press

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about MODERNA, INC.
05:19pMODERNA : U.S. administers 345.6 mln doses of COVID-19 vaccines - CDC
RE
04:55pMODERNA : U.S. CDC Says Delivered 400,675,525 Doses Of COVID-19 Vaccine As Of Ju..
RE
07/30MODERNA : U.S. administers 344.93 mln doses of COVID-19 vaccines - CDC
RE
07/30MODERNA : Most COVID-19 cases in Massachusetts outbreak among vaccinated, says C..
RE
07/30MODERNA : U.S. CDC Says Delivered 399,090,105 Doses Of Covid-19 Vaccine As Of Ju..
RE
07/30CORONAVIRUS - BOTSWANA : No vaccine manufacturing company has withdrawn from an ..
AQ
07/30Misleading With Numbers
AQ
07/30States race to use COVID-19 vaccines before they expire
AQ
07/29MODERNA : Conservatives push feds to ensure Canadians who got mixed vaccines can..
AQ
07/29MODERNA : U.S. administers 344.1 mln doses of COVID-19 vaccines - CDC
RE
More news
Financials (USD)
Sales 2021 19 103 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 14,0x
Yield 2021 -
Capitalization 142 B 142 B -
EV / Sales 2021 6,81x
EV / Sales 2022 7,64x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 353,60 $
Average target price 187,73 $
Spread / Average Target -46,9%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 837
PHARMARON BEIJING CO., LTD.64.43%23 159